Siegfried Group is a leading global CDMO with 150+ years of pharmaceutical and chemical heritage, operating 13 production sites across Switzerland, Germany, Spain, France, Malta, the USA, and China. The company provides integrated services from early-phase API development through commercial-scale drug substance and drug product manufacturing, including exclusive synthesis, generic APIs, controlled substances, HPAPI handling, sterile formulations, and viral vector manufacturing through subsidiary DINAMIQS. In January 2026, Siegfried announced acquisition of additional US-based small molecule drug substance capacity.
small molecule API development and commercial manufacturing, exclusive synthesis, controlled substances, HPAPI handling, sterile fill/finish, ophthalmic drugs, viral vector manufacturing (DINAMIQS)
6 sites worldwide
No reviews available yet.
No documents available.